A randomized phase 3 trial by the ECOG-ACRIN Cancer Research Group found that combining temozolomide chemotherapy with radiation therapy significantly improves the long-term survival of patients with slow-growing, low-grade gliomas compared to radiation therapy alone. The trial followed 172 patients for over 10 years and showed a 70% survival rate with combined treatment versus 47% with radiation alone. The results, presented at a neuro-oncology meeting, have immediate clinical implications. While temozolomide did increase toxicity, the survival benefit was consistent across different types of gliomas. Additional studies will explore quality of life and molecular data from the trial.
Source link
Adding temozolomide to radiation therapy improves survival in adult patients with slow-growing brain tumor, trial finds
